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In December 2019, an infectious disease caused by the coronavirus SARS-CoV-2
appeared in Wuhan, China. This disease (COVID-19) spread rapidly worldwide, and
on March 2020 was declared a pandemic by the World Health Organization (WHO).
Today, almost 1,5 million people have been infected, with more than 85,000 casualties.
Today, no vaccine nor antiviral drug is available. While the development of a vaccine
might take at least a year, and for a novel drug, even longer; finding a new use to an old
drug (drug repurposing) could be the most effective strategy. We present a docking-
based screening using a quantum mechanical scoring of a library built from approved
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drugs and compounds undergoing clinical trials, against three SARS-CoV-2 target pro-
teins: the spike or S-protein, and two proteases, the main protease and the papain-like
protease. The S-protein binds directly to the Angiotensin Converting Enzyme 2 recep-
tor of the human host cell surface, while the two proteases process viral polyproteins.
Following the anaylysis of our structure-based compound screening, we propose several
structurally diverse compounds (either FDA-approved or in clinical trials) that could
display antiviral activity against SARS-CoV-2. Clearly, these compounds should be
further evaluated in experimental assays and clinical trials to confirm their actual ac-
tivity against the disease. We hope that these findings may contribute to the rational
drug design against COVID-19.
Introduction
Coronaviruses (CoVs) usually are the cause of mild to serious respiratory tract infections.
In the past decades, two highly pathogenic CoVs, the severe acute respiratory syndrome
coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-
CoV), both transmitted from animals to humans, triggered global epidemics, in 2003 and
2012, respectively, with high mortality rates.1 In December 2019, a coronavirus infectious
disease (named COVID-19) was detected in Wuhan, province of Hubei, China, caused by a
new pathogenic CoV, named SARS-CoV-2. The virus spread very rapidly from China to all
countries, and on March 11th, 2020, it was declared a pandemic by the World Health Orga-
nization (WHO). At the time of this writing, there are almost 1,5 million cases worldwide,
with more than 85,000 fatalities;2 no country has been spared of this disease. The mortality
rate of the SARS-CoV-2 is currently estimated in the range of 0.5-6%; and while COVID-19
appears to be less deadly than SARS (∼10%)3 or MERS (∼40%),3 it seems to be more
contagious, with a reproductive number (Ro) in the range 2.0-6.5,4 higher than SARS and
MERS, which could explain the velocity of its propagation.
Today, no specific therapeutics are available, and current disease management is limited
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to social measures, such as social distancing, travel ban, and full lockdown in many cities.
Thus, there is an urgent need for the discovery of prevention and treatment strategies for the
COVID-19. It is acknowledged that the development and evaluation of a vaccine might take
at least a year. While the discovery and evaluation of a new drug should take even longer,
the use of an existing drug (or compound undergoing clinical trials) to treat COVID-19
(drug repurposing) seems the fastest strategy, since these compounds have either regulatory
approval as drugs or have cleared safety studies that indicate a therapeutic potential.
While some pharmaceuticals are currently being tested,5,6 there is a clear need to de-
velop new alternatives within the drug repurposing approach. In this contribution, we per-
form molecular docking-based virtual screening using quantum mechanical (QM) scoring,7–9
and a docking library built from approved Food and Drug Administration (FDA) drugs
and compounds undergoing clinical trial on the following three viral target proteins: the
spike glycoprotein (S-protein), and two proteases, namely, the 3-chymotrypsin-like protease
(3CLpro) [or main protease (Mpro)], and the papain-like protease (PLpro). The S-protein
binds directly to the Angiotensin Converting Enzyme 2 (ACE2) receptor of the human host
cell surface –thus enabling virus entry and replication, and the two proteases process the two
viral polyproteins encoded by the open reading frames (ORFs) orf1a and orf1b. It has been
shown that the PLpro also have de-ubiquitination and de-ISGylation activities in SARS and
MERS.
From our virtual screening, we suggest a variety of compounds (either FDA-approved or
in clinical trials) that may inhibit SARS-CoV-2. Needless to say, these compounds should
be evaluated in ad hoc experimental assays and clinical trials to confirm their actual activity
against COVID-19. This contribution complements earlier works in the field,10–17 and it
is our hope to thus collaborate to the worldwide efforts to deliver a prompt answer to the
deadly threat of COVID-19.
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Results and Discussion
We docked a chemical library of 11,552 compounds (composed by FDA-approved, investiga-
tional and experimental drugs, cf. the Methods section for details) onto three different pro-
teins of the SARS-CoV-2: the Mpro, the PLpro, and the S-protein. In all targets, molecules
were scored with the QM docking score (QMDS).7 QM methods capture the underlying
physics of the molecular system accounting for all energy contributions, including electronic
polarization, covalent-bond formation, and charge transfer.8 For each target, we then ana-
lyzed the 1% top-scoring molecule subset, selecting candidates in terms of their QMDS, the
presence of key interactions with the receptor, and visual inspection.
For the Mpro, we used two experimental structures: Mpro bound to peptide N3 (PDB
6LU7)18 and the unbound form of the protein (PDB 6YB7). The purpose of using two
structures for docking is to account to some extent for protein flexibility by receptor ensemble
docking.19,20 After docking, scoring, and ranking the molecules of the chemical library on
each receptor, the hit-lists were merged and the best ranking pose for each molecule was
kept (according to the merging-and-shrinking method21,22).
Self-docking of peptide N3 onto structure 6LU7 had a root-medium-square deviation
(RMSD) of 1.7 Å (an excellent result for a peptide), while according to its QMDS, N3 was
within the top 0.3% of the docked library; this is a simple but necessary validation of our
approach. Following the criteria described above, we hereby describe a list of potential in-
hibitors: Ritonavir (DrugBank ID DB00503) (Figure 1), Indinavir (DB00224) and Lopinavir
(DB01601), which are FDA-approved drugs which act as HIV protease inhibitors, and are
used to treat HIV/AIDS; Brilacidin (ChEMBL ID CHEMBL2219413) (Figure 1) an investi-
gational drug for the supportive care of mucositis, stomatitis, and head and neck neoplasms
(interestingly, Brilacidin is being investigated for direct inhibition of SARS-CoV-2 (press
release of April 6th, 201023); Samatasvir (CHEMBL3039519) an investigational drug that
has been used in trials as a treatment for hepatitis C infection; CR665 (DB05155) an inves-
tigational drug for the development of highly selective peripheral κ-opioid receptor agonists.
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Considering the large size of the binding site, other larger molecules have been identified,
such as Antiogensinamide (DB13517), a potent vasoconstrictor used as a cardiac stimulant,
and Felypressin (DB00093), an investigational synthetic peptide used as a vasoconstrictor.
Other experimental drugs have been also identified, such as DB02747, DB04692, DB04722,
and DB03311 (Figure 2). A list of potential inhibitors of the Mpro is summarized in Table 1.
Figure 1: Ritonavir (left panel) and Brilacidin (right panel) docked within the binding site
of SARS-CoV-2 Mpro. The receptor surface is colored as: red, oxygens; blue, nitrogen; white,
polar hydrogen; grey, non-polar atoms. On the right panel, native ligand N3 (6LU7) is also
displayed with white carbon atoms superimposed to Brilacidin (yellow carbons). Figure
prepared with ICM (Molsoft LLC, San Diego, CA).
Figure 2: Experimental drugs identified as potential inhibitors of the SARS-CoV-2 Mpro: A,
DB02747; B, DB04692; C, DB04722; D, DB03311
Since at the time of this writing there is no experimental structure available of SARS-
CoV-2 PLpro, this protease was modeled by homology based on the experimental crystal
structure of SARS-CoV PLpro complexed with the benzamide derivative GRL061724 (PDB
3E9S). Both proteases share 82% sequence identity, and 100% within the binding site. It
should be highlighted that targeting PLpro with antiviral drugs may not only block viral
replication but also could inhibit the dysregulation of signaling cascades in infected cells
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Table 1: Potential inhibitors of SARS-CoV-2 Mpro from existing drugs and compounds un-
dergoing clinical trials (DB, DrugBank; CH, ChEMBL).
Drug name Drug ID Pharmacological function
Felypressin DB00093 Vasoconstrictor
Angiotensinamide DB13517 Vasoconstrictor
Briladicin CH2219413 Head and neck neoplasms
Ritonavir DB00503 HIV-protease inhibitor
Samatasvir CH3039519 Hepatitis C infection
Indinavir DB00224 HIV-protease inhibitor
CR665 DB05155 κ-opioid receptor agonists





that may lead to cell death in other uninfected cells.25
From our analysis based on the criteria mentioned above, we identified several potential
inhibitors of PLpro, of which we can highlight the following: Pilaralisib (CHEMBL3360203),
an orally available selective small-molecule that inhibits the phosphoinositide-3 kinase (PI3K),
that has been used in trials studying the treatment of different types of cancer, such as
lymphoma, solid tumors, and glioblastoma; Tiracizine (DB13635), a dibenzazepine and an
experimental anti-arrhythmic agent (Figure 3); PF-610355 (DB11871), an inhalable long-
acting β2 adrenoreceptor agonist that was investigated some years ago for the treatment of
asthma; Compound DB07665, an experimental drug which targets prothrombin; Cilazapril
(DB01340), an FDA-appoved ACE inhibitor for the treatment of hypertension and heart
failure (cilazapril is in fact a prodrug that is hydrolyzed to its main metabolite cilazaprilat;
however, the structural differences of the prodrug and its active form share the same pose
within the binding site); Indisulam (CHEMBL77517), a sulfonamide investigational com-
pound with potential antineoplastic activity (Figure 3), which inhibits the cyclin-dependent
kinase (CDK), which is usually over-expressed in cancerous cells; Compound DB03082, an
experimental naphtamide derivative which shows activity as a urokinase-type plasminogen
activator; Denibulin (DB05932), an investigational molecule under development for the treat-
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Figure 3: Indisulam (left panel) and Tiracizine (right panel) docked within the binding site of
SARS-CoV-2 PLpro. The receptor surface is colored as: red, oxygens; blue, nitrogen; white,
polar hydrogen; grey, non-polar atoms. The surface corresponding to amino-acids 270-273
(which forms the other wall of the channel where the molecules lie) is omitted for the sake
of clarity. Figure prepared with ICM (Molsoft LLC, San Diego, CA).
ment of solid tumor cancers; Picotamide (DB13327), an experimental antiplatelet agent
which acts as a thromboxane synthase inhibitor and a thromboxane receptor inhibitor. There
are several other benzamide derivatives experimental drugs which can be considered as can-
didates, such as DB01748, DB08656, DB02861, CHEMBL1257015, and DB02429; moreover,
benzamides have been reported to bind also to SARS-CoV and MERS-CoV PLpro.26
A list of potential inhibitors for SARS-CoV-2 of PLpro is summarized in Table 2.
The SARS-CoV-2 spike-protein (S-protein) receptor binding domain (RBD) binds to the
Table 2: Potential inhibitors of SARS-CoV-2 PLpro from existing drugs and compounds
undergoing clinical trials (DB, DrugBank; CH, ChEMBL).
Drug name Drug ID Pharmacological function
Pilaralisib CH3360203 PI3K inhibition
Tiracizine DB13635 Anti-arrhythmic agent
PF-610355 DB11871 β2 adrenoreceptor agonist
Cilazapril DB01340 ACE inhibitor for hypertension
Indisulam CH77517 Antineoplastic activity
Denibulin DB05932 Treatment of solid tumor cancers






ACE2 receptor in the host cell, and thus may represent an attractive drug target. Experi-
mental structures of the RBD in complex with ACE2 have been very recently obtained,27,28
so we isolated the RBD from one of them (PDB 6LZG), and docked and scored our library of
approved drugs. It should be borne in mind that the RBD interface that should be targeted
to preclude its interaction with ACE2 is not a buried binding site, a somehow shallow surface.
Thus, the top scoring compounds are usually large and flexible molecules (such as Somas-
tostatin and Daptomycin), and further validation using, for example, molecular dynamics,
should be considered for prioritizing compounds before experimental evaluation. Potential
inhibitors include Pralatrexate (DB06813), which is an approved drug for the treatment of
relapsed or refractory peripheral T-cell lymphoma, Carumonam (DB13553), an experimental
antimicrobial drug, Bradykinin (DB12126), which has been investigated for the treatment
of hypertension and type 2 diabetes, Aclerastide (DB12631), an investigational drug for the
treatment of diabetic foot, angiotensin II (DB11842), and granotapide (CHEMBL 4297618),
which has been used in trials for the treatment of type 2 diabetes mellitus.
Conclusions
The infectous respiratory disease COVID-19 originated in Wuhan, China in December 2019,
and rapidly expanding throughout the world is a serious threat to global health, totalizing at
the time of this writing more than 1.5 million infected people, and more than 80,000 fatalities.
So far, neither a vaccine nor an approved drug are currently available to treat this disease.
Considering the time required to develop any of those options, drug repurposing seems the
most appealing and straightforward approach. In this contribution, we performed docking-
based virtual screening on three SARS-CoV-2 targets (the proteases Mpro and PLpro, and
the spike glycoprotein) using an in-house library of approved FDA drugs and investigational
and experimental drugs to suggest potential compounds which may act as antivirals. While
further experimental validation and clinical trials are necessary to confirm their activity
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against COVID-19, we join our effort to that of many other researchers to come up with an
urgent and effective solution to this threat.
Methods
Molecular system setup
The structures of the SARS-CoV-2 Mpro bound to peptide inhibitor N3 (PDB 6LU7) and
unbound (PDB 6YB7), the SARS-CoV-2 S-protein bound to ACE2 (PDB 6M17), and the
SARS-CoV (PLpro) complexed with ligand GRL0617 (PDB 3E9S) were downloaded from
the Protein Data Bank (PDB) and prepared using the ICM software29 (MolSoft, San Diego,
CA, 2019) in a similar fashion as in earlier works.30 Succinctly, hydrogen atoms were added,
followed by a short local energy minimization in the torsional space; the positions of polar
and water hydrogens were determined by optimizing the hydrogen bonding network, and
then all water molecules were deleted. All Asp and Glu residues were assigned a -1 charge,
and all Arg and Lys residues were assigned a +1 charge. Histidine tautomers were chosen
according to their corresponding hydrogen bonding pattern.
Database preparation
The docking library was constructed by merging molecule subsets from four different li-
braries: i) ChEMBL31 (Version 26) (including molecules which reached at least phases 1,
2, 3 or 4); ii) DrugBank Version 5.1.5.32 (including chemical databases of Approved, Ex-
perimental and Investigational drugs); iii) the DrugCentral database of approved drugs;33
iv) the FDA-approved library from Selleck Chem.34 Redundant entries were eliminated, and




The SARS-CoV-2 PLpro was modeled using the SARS-CoV PLpro bound to benzamide deriva-
tive GRL0617 (3E9S) as template. The two proteins are highly similar (82% sequence iden-
tity), with a 100% conservation within the binding site (Figure 4). A crude model was built,
and then refined through local energy minimization using ICM. Taking into account the
binding site conservation, and to avoid pocket collapse, ligand GRL0617 was kept during the
refinement process, in a ligand-steered modeling fashion.30,35,36
Molecular docking and quantum mechanical scoring
Protein-molecule complexes were generated through flexible-ligand:rigid-receptor molecular
docking with ICM, followed by structural relaxation to optimize protein-molecule interactions
through cycles of local energy minimization; in this local energy minimization, amino-acids
within 4 Å of any docked molecule were considered free. For each target, all amino-acids
within 8 Å of any docked molecule were then collected, and used to build a reduced system,
capping the N- and C-terminal of each fragment of the cut-out system with hydrogens (cf.
Ref.7 for details on the relaxation process and system cutout).
The quantum mechanical docking score7 (QMDS ) on the reduced system was calculated
according to
QMDS = ∆GQMo + ∆G
QM
conf (P ) + ∆G
QM
conf (L)− T∆S , (1)
where the “o” subscript in the first term refers to the difference of the free energy calculated
using the protein-ligand (PL), protein (P) and ligand (L) conformations from the docked
complex, the fourth term corresponds to the change in conformational entropy, and the
second and third terms are calculated as
∆GQMconf (X) = G
QM
o (X)−GQM(X) , (X = L,P) (2)
where GQMo (X) is the energy of the isolated X in the conformation of the docked PL complex,
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Figure 4: Sequence alignment of the papain-like proteases PLpro corresponding to SARS-CoV
and SARS-CoV-2. Amino-acid conservation is shown on top (the sequence identity is 82%).
It can be observed that amino-acids in the binding site of SARS-CoV in contact with ligand
GRL0617 (shown in grey) are fully conserved in SARS-CoV-2. A schematic representation of
the secondary structure, corresponding to the template structure of SARS-CoV PLpro (PDB
3E9S), is shown below the secuences as cylinders (helices) and arrows (β-sheets). Figure
prepared with ICM (Molsoft LLC, San Diego, CA)
andGQM(X) is the energy of X in the free unbound state. The unbound states were generated
through local energy minimization on both protein and molecule in isolation. The binding
conformational entropy was calculated as
∆S = −R ln Ω , (3)
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assuming that upon binding the molecule adopts a single conformational state (thus Sbound =
0), and where Ω is the number of diverse torsional conformations of the molecule in its free
state, calculated by performing a Monte-Carlo (MC) sampling with local energy minimization
in the torsional space using ICM,29,37 and collecting all structurally different conformations
within the lowest 3 kcal/mol energy (it is assumed that all conformers are equally probable).
QM calculations were performed using the MOPAC2016 software38 and its linear-scaling
module MOZYME,39 using the semi-empirical PM7 Hamiltonian.40 The solvation energy
contribution in aqueous environment was calculated according to the COnductor Like Screen-
ing Model (COSMO),41 continuum solvent model, with default atomic radii and surface ten-
sion parameters. The solvent-accessible surface area was extracted from the MOPAC2016
output (cf. http://openMOPAC.net for details).
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